Business
Business update
Trellus Health plc reported progress in its clinical trials and pharmaceutical verticals, securing a 12-month contract with ICON plc for Takeda-sponsored trials and a similar contract with PSI Inc. for Sanofi-sponsored trials, alongside ongoing support for an AstraZeneca Phase 2 trial. The company also advanced its collaboration with Johnson & Johnson and renewed its agreement with Pfizer, while expecting revenue of approximately $545,000 for the year ended 2025 and reducing its monthly cash burn to around $400,000. A £5 million convertible facility with Alumni Capital LLC was approved, with the first tranches totaling £737,500 expected to extend the cash runway into late Q1 2026, and discussions for further funding are ongoing. Disclaimer*
About this update from Trellus Health Plc
[{"type":"text","content":"\n\nTrellus Health plc\n(\"Trellus Health\", the \"Company\" or the \"Group\")\n \nBusiness update\n \nLONDON, U.K. AND NEW YORK, U.S. (3 February 2026). Trellus Health plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programmes and value-based solutions to manage complex chronic conditions, provides the following business update.\n \nOperational and Commercial Progress\nSince the Company's interim results for the six months ended 30 June 2025, Trellus Health has continued to make progress across its core strategic verticals, with particular momentum in the clinical trials sector.\n \nClinical Trials Vertical\n \n· In October 2025, the Company entered into a 12-month contract with ICON plc, a global contract research organisation (\"CRO\"), to support recruitment and enrolment optimisation for an ongoing mid-stage immunology and inflammation clinical trial sponsored by Takeda. The contract includes an upfront fee, monthly management fees and milestone-based payments linked to defined performance indicators.\nThe Company has begun launching the program into agreed-upon sites.\n\n· Later in October 2025, the Company entered into a second 12-month commercial contract with PSI Inc., another global CRO, to deploy its Trellus TrialSet™ solution across two late-stage immunology and inflammation clinical trials sponsored by Sanofi. This represents the Company's second commercial CRO contract following the launch of TrialSet™. The Company is implementing the programme now and expects to be fully launched in mid-Q1.\n\n· In addition, Trellus Health® continues to support an ongoing Phase 2 IBD clinical trial pursuant to its licensing agreement with AstraZeneca.\n\n· The Company has been granted preferred vendor status by both ICON plc and PSI Inc., which is expected to facilitate access to pharmaceutical sponsors and streamline future contracting processes.\n \nPharmaceutical and Patient Support Programmes\n· The collaboration with Johnson & Johnson Health Care Systems Inc., signed in January 2025, continues to progress. During the pilot phase, engagement ...